# US 2023/0067929 A1 · Heterocyclic derivatives, pharmaceutical compositions and their use in the treatment, amelioration or prevention of cancer

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0067929 A1
- Document ID: US20230067929A1
- Status: Published application
- Kind: A1
- Application number: 17/413,798
- Filed: 2019-12-17
- Published: 2023-03-02
- Earliest claimed: 2018-12-17
- Assignees: Tolremo Therapeutics AG
- Applicants: Tolremo Therapeutics AG
- Inventors: Stefanie Flückiger-Mangual; Dorothea Gruber; Gerhard Müller; Johan J.N. Veerman; Rutger Folmer
- Web page: https://patentgrep.com/patent/US20230067929A1

## CPC

- C07D 471/04: Ortho-condensed systems
- A61K 31/506: not condensed and containing further heterocyclic rings
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 35/00: Antineoplastic agents
- C07D 401/04: directly linked by a ring-member-to-ring-member bond
- C07D 401/14: containing three or more hetero rings
- C07D 405/14: containing three or more hetero rings
- C07D 409/14: containing three or more hetero rings
- C07D 413/14: containing three or more hetero rings
- C07D 417/14: containing three or more hetero rings
- C07D 471/08: Bridged systems
- C07D 495/04: Ortho-condensed systems
- C07D 498/18: Bridged systems
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to a compound of formula (I), optionally in the form of a pharmaceutically acceptable salt, solvate, cocrystal, tautomer, racemate, enantiomer, or diastereomer or mixture thereof Formula (I) and to pharmaceutical compositions comprising a compound of formula (I), as well as to the use of a compound of formula (I), or a pharmaceutically acceptable salt, solvate, cocrystal, tautomer, racemate, enantiomer, or diastereomer or mixture thereof, in the treatment of cancer. Further aspects of the present invention include combination therapies in which a compound of formula (I), as well as to the use of a compound of formula (I), or a pharmaceutically acceptable salt, solvate, cocrystal, tautomer, racemate, enantiomer, or diastereomer or mixture thereof, is used in combination with a known anti-cancer agent.

## Claims

### Claim 1

A compound of formula (I), optionally in the form of a pharmaceutically acceptable salt, solvate, cocrystal, tautomer, racemate, enantiomer, or diastereomer or mixture thereof
wherein
R1 is selected from halogen and -(optionally substituted hydrocarbon group which contains from 1 to 20 carbon atoms and optionally 1 to 15 heteroatoms selected from O, N and S);
R2 is L-R21, wherein L is selected from —C(O)—, —C(O)—O—, —C(O)—NH—; and
R21 is selected from hydrogen, -(optionally substituted C1-6 alkyl) which may contain one to three oxygen atoms between carbon atoms, and -(optionally substituted C3-6 cycloalkyl);
R3 is selected from -(optionally substituted heterocyclyl), -(optionally substituted carbocyclyl), -(optionally substituted C1-6 alkylene)-(optionally substituted heterocyclyl) and -(optionally substituted C1-6 alkylene)-(optionally substituted carbocyclyl);
G is selected from a bond, —C(R11)2—, —N(R11)— and —O—, wherein each R11 is selected from -hydrogen, —C1-6-alkyl, and —(C1-6-alkyl substituted with one or more F); wherein R1 and any R11 can be optionally linked;
each of X1, X2 and X3 is independently selected from N, CH and CRx, wherein at least one of said X2 and X3 is N;
Z is —N(R31)—, wherein R31 is selected from -hydrogen, —C1-6-alkyl, and —(C1-6-alkyl substituted with one or more F); wherein R3 and any R31 can be optionally linked; and
E is either absent or is selected from —CH2—, —CHRx—, —CRx2—, —NH—, —NRx—, —O—, -L1-L2- and -L2-L1-, wherein L1 is selected from —CH2—, —CHRx—, —CRx2—, —NH—, —NRx— and —O— and L2 is selected from —CH2—, —CHRx— and —CRx2—;
wherein Ring A may be substituted with one or more groups Rx, wherein any two Rx groups at ring A can be optionally linked and/or any Rx group at ring A can be optionally linked with R2;
wherein Ring A may furthermore be substituted to form a bicyclic moiety having the following partial structure:
wherein Ring B is an -(optionally substituted heterocycle) or -(optionally substituted carbocycle);
each Rx is independently selected from -halogen, —OH, —O-(optionally substituted C1-6 alkyl), —NH-(optionally substituted C1-6 alkyl), —N(optionally substituted C1-6 alkyl)2, ═O, -(optionally substituted C1-6 alkyl), -(optionally substituted carbocyclyl), -(optionally substituted heterocyclyl), -(optionally substituted C1-6 alkylene)-(optionally substituted carbocyclyl), -(optionally substituted C1-6 alkylene)-(optionally substituted heterocyclyl), —O-(optionally substituted C1-6 alkylene)-(optionally substituted carbocyclyl), and —O-(optionally substituted C1-6 alkylene)-(optionally substituted heterocyclyl), and
wherein the optional substituent of the optionally substituted hydrocarbon group, optionally substituted C3-6 cycloalkyl, optionally substituted heterocyclyl, optionally substituted heterocycle, optionally substituted carbocyclyl, optionally substituted carbocycle and optionally substituted C1-6 alkylene is independently selected from —(C1-6 alkyl which is optionally substituted with one or more halogen), -halogen, —CN, —NO2, oxo, —C(O)R*, —COOR*, —C(O)NR*R*, —NR*R*, —N(R*)—C(O)R*, —N(R*)—C(O)—OR*, —N(R*)—C(O)—NR*R*, —N(R*)—S(O)2R*, —OR*, —O—C(O)R*, —O—C(O)—NR*R*, —SR*, —S(O)R*, —S(O)2R*, —S(O)2—NR*R*, —N(R*)—S(O)2—NR*R*, heterocyclyl which is optionally substituted with halogen or C1-6 alkyl, and carbocyclyl which is optionally substituted with halogen or C1-6 alkyl; wherein each R* is independently selected from H, C1-6 alkyl which is optionally substituted with halogen, heterocyclyl which is optionally substituted with halogen or C1-6 alkyl, and carbocyclyl which is optionally substituted with halogen or C1-6 alkyl; wherein any two R* connected to the same nitrogen atom can be optionally linked, and
wherein the optional substituent of the optionally substituted C1-6 alkyl and of the optionally substituted C1-6 alkylene is independently selected from -halogen, —CN, —NO2, OXO, —C(O)R**, —COOR**, —C(O)NR**R**, —NR**R**, —N(R**)—C(O)R**, —N(R**)—C(O)—OR**, —N(R**)—C(O)—NR**R**, —N(R**)—S(O)2R**, —OR**, —O—C(O)R**, —O—C(O)—NR**R**, —SR**, —S(O)R**, —S(O)2R**, —S(O)2—NR**R**, and —N(R**)—S(O)2—NR**R**; wherein R** is independently selected from H, C1-6 alkyl which is optionally substituted with halogen, heterocyclyl which is optionally substituted with halogen or C1-6 alkyl, and carbocyclyl which is optionally substituted with halogen or C1-6 alkyl; wherein any two R** connected to the same nitrogen atom can be optionally linked.

### Claim 2 (depends on 1)

The compound according to claim 1, wherein the compound of formula (I) is a compound of formula (Va)
wherein R21 is selected from C1-2 alkyl, C1-2 haloalkyl and C3-4 cycloalkyl.

### Claim 3 (depends on 1, 2)

The compound according to claim 1 or claim 2, wherein the compound of formula (I) is a compound of formula (Vc)

### Claim 4

The compound according to any one of the preceding claims, wherein the compound of formula (I) is a compound of formula (IVd)
wherein R6x is selected from C1-3 alkyl and C1-2 haloalkyl.

### Claim 5

The compound according to any one of the preceding claims, wherein R2 is —C(O)—R21, and wherein R21 is —CH3 or —CH2CH3.

### Claim 6

The compound according to any one of the preceding claims, wherein R2 is —C(O)—R21, and wherein R21 is —CH3.

### Claim 7

The compound according to any one of the preceding claims, wherein R31 is selected from -hydrogen and —C1-2-alkyl, and wherein preferably R31 is -hydrogen.

### Claim 8

The compound according to any one of the preceding claims, wherein E is selected from —CH2—, —CHRx—, —NH—, —NRx—, —O—, -L1-L2- and -L2-L1-, wherein L1 is selected from —CH2—, —CHRx—, —NH—, —NRx— and —O— and L2 is selected from —CH2— and —CHRx—, and preferably wherein E is —CH2.

### Claim 9

The compound according to any one of the preceding claims, wherein the number of groups Rx in Ring A is 0, 1, or 2.

### Claim 10

The compound according to any one of the preceding claims, wherein both X2 and X3 are nitrogen.

### Claim 11

The compound according to any one of the preceding claims, wherein X1 is CH.

### Claim 12

The compound according to any one of the preceding claims, wherein each Rx is independently selected from -halogen, —OH, —O—C1-2 alkyl optionally substituted with one or more Rxa, —NH—C1-2 alkyl optionally substituted with one or more Rxa, —N(C1-2 alkyl optionally substituted with one or more Rxa)2, ═O, C1-3 alkyl optionally substituted with one or more Rxa, C1-2 haloalkyl, —W-(monocyclic carbocyclyl optionally substituted with one or more Rxa), —W-(monocyclic heterocyclyl optionally substituted with one or more Rxa), and wherein —W— is absent, —(C1-2 alkylene)- or —O—(C1-2 alkylene)-, and wherein monocyclic carbocyclyl is selected from phenyl and C3-6 cycloalkyl, and wherein monocyclic heterocyclyl is selected from thiophenyl, pyridyl, pyrazinyl and pyrimidinyl, and wherein said Rxa is independently selected from —Cl, —F, and —OH.

### Claim 13

The compound according to any one of the preceding claims, wherein G is absent and R1— is selected from -(optionally substituted heterocyclyl) and -(optionally substituted carbocyclyl).

### Claim 14

The compound according to any one of the preceding claims, wherein G is absent and R1 is phenyl, azaindolyl, azaindazolyl, pyrazinyl, pyridyl or pyrimidinyl, wherein the phenyl, azaindolyl, azaindazolyl, pyrazinyl, pyridyl or pyrimidinyl is optionally substituted with one or more, preferably one or two, substituents selected from halogen, —C1-6 alkyl, C1-6 haloalkyl, —O—(C1-6 alkyl), —O—(C1-6 haloalkyl), —C(O)—C1-6 alkyl, —C(O)—C1-6 haloalkyl, —NH—C(O)—C1-6 alkyl, —NH—C(O)—C1-6 haloalkyl and —C(O)—NH—C1-6 alkyl, —C(O)—NH—C1-6 haloalkyl.

### Claim 15

The compound according to any one of the preceding claims, wherein R3 is phenyl or pyridyl, each of which is optionally substituted with one or more groups selected from halogen, —(C1-6 alkyl which is optionally substituted with one or more F) and —O—(C1-6 alkyl which is optionally substituted with one or more F).

### Claim 16

The compound according to any one of the preceding claims, wherein the compound of formula (I) binds to the bromodomain of p300 and/or the bromodomain of CBP with an EC50 of 10000 nM or less.

### Claim 17 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16)

A pharmaceutical composition comprising:
a compound having the formula (I) as defined in any of claims 1 to 16, optionally in the form of a pharmaceutically acceptable salt, solvate, cocrystal, tautomer, racemate, enantiomer, or diastereomer or mixture thereof,
and optionally one or more pharmaceutically acceptable excipient(s) and/or carrier(s).

### Claim 18 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17)

A compound having the formula (I) as defined in any of claims 1 to 16, optionally in the form of a pharmaceutically acceptable salt, solvate, cocrystal, tautomer, racemate, enantiomer, or diastereomer or mixture thereof, or the pharmaceutical composition of claim 17, wherein the compound or pharmaceutical composition is for use in the treatment, amelioration or prevention of cancer.

### Claim 19 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17)

A method of treating, ameliorating or preventing cancer, the method comprising administering to a patient in need thereof a therapeutically effective amount of a compound having the formula (I) as defined in any of claims 1 to 16, optionally in the form of a pharmaceutically acceptable salt, solvate, cocrystal, tautomer, racemate, enantiomer, or diastereomer or mixture thereof, or a pharmaceutical composition of claim 17.

### Claim 20 (depends on 18, 19)

A compound for use according to claim 18, a pharmaceutical composition for use according to claim 18 or the method according to claim 19, wherein the cancer is selected from melanoma, non-small cell lung cancer, prostate cancer, bile duct cancer, bladder cancer, pancreatic cancer, thyroid cancer, ovarian cancer, colorectal tumor, hairy cell leukemia, acute myeloid leukemia, multiple myeloma, liver cancer, breast cancer, esophageal cancer, head and neck cancer and glioma, in particular melanoma and non-small cell lung cancer.

### Claim 21 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17)

A method of treating, ameliorating or preventing cancer, the method comprising administering to a patient in need thereof a therapeutically effective amount of a compound having the formula (I) as defined in any of claims 1 to 16, optionally in the form of a pharmaceutically acceptable salt, solvate, cocrystal, tautomer, racemate, enantiomer, or diastereomer or mixture thereof, or a pharmaceutical composition of claim 17, wherein the method further comprises administering to the patient in need thereof a second therapeutic agent.

### Claim 22 (depends on 21)

The method of claim 21, wherein the second therapeutic agent is an immune-oncology agent.
